Men’s Health

Scans could reduce the number of those who are over-diagnosed by 5%

A new study in the US has revealed that prostate cancer screening by digital rectal exam and PSA testing is disappearing from primary care practice there.

The prevalence of PSA screening has decreased, particularly among men under the age of 75 years, following the US Preventative Services Task Force (USPSTF) recommendation against screening all men in 2012.

In prostate brachytherapy, the radiation source is placed close to the tumour, Gary Culliton reports in his latest Clinical Update.

Abiraterone acetate is now reimbursed on the high-tech drug scheme for men with metastatic castration-resistant prostate cancer (mCRPC) post-androgen deprivation therapy (ADT).

“It is known that men who have prostate cancer are more likely to die of their disease if they are overweight or obese than if they are of a healthy weight,” according to Dr Stephen Finn, Associate Professor in Histopathology and Morbid Anatomy in Trinity College Dublin and Consultant Pathologist at St James’s Hospital.

In the largest prospective study to date of image-guided technology for identifying suspicious regions of the prostate to biopsy, researchers compared the ability of this technology to detect high-risk prostate cancer with that of the current standard of unguided prostate biopsy.

Clearly, not every prostate cancer patient will benefit from novel endocrine treatments, Gary Culliton reports in his latest Clinical Update.

Three-quarters of prostate cancer survivors suffer long-term side-effects, according to a new study led by Queen’s University Belfast.

Regaining normal erectile function is rare after radical prostatectomy, according to a new study presented at the 15th annual European Association of Urology Congress, which took place in Madrid last week (March 20-24).